Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label single arm multicenter phase II trial assessing anlotinib with chemotherapy in patients with stage IIB classic osteosarcoma of the extremity

Next Previous
Trial Profile

An open label single arm multicenter phase II trial assessing anlotinib with chemotherapy in patients with stage IIB classic osteosarcoma of the extremity

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catequentinib (Primary) ; Cisplatin (Primary) ; Doxorubicin (Primary)
  • Indications Osteosarcoma
  • Focus Therapeutic Use
  • Acronyms ALTER-S002

Most Recent Events

  • 16 Jul 2024 New trial record
  • 04 Jun 2024 Results reporting an update on the effectiveness and safety of the follow-up presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top